Correlation between radiomic features of Crohn's disease and secondary loss of response to infliximab

Table 2 Demographic univariate and multivariate analyses based on the training cohort

Clinical factors	Univariate analysis			Multivariate analysis
	Loss of response (n = 47)	Response (n = 109)	P value	β	P value	OR (95%CI)
Age (years)	25 (18, 34)	25 (20, 30.5)	0.902
Gender (male/female)	12/35	33/76	0.549
Disease duration (months)	24 (12, 48)	12 (4, 36)	0.011	-0.012	0.041	0.988 (0.976, 0.999)
Montreal location, n (%)
Ileal (L1)	9 (19.1)	12 (11.0)	0.168
Colonic (L2)	13 (27.7)	30 (27.5)	0.575
Ileocolonic (L3)	25 (53.2)	67 (61.5)	0.319
Montreal behavior, n (%)
Nonstricturing, nonpenetrating (B1)	38 (81.0)	67 (61.5)	0.687
Stricturing (B2)	7 (14.9)	32 (29.4)	0.056
Penetrating (B3)	3 (6.4)	19 (17.4)	0.069
Perianal disease modifier (P)	24 (51.1)	58 (53.2)	0.805
Smoking (yes)	3 (6.4)	5 (4.6)	0.641
CRP (mg/L)	17.70 (8.85, 40.10)	11.10 (3.55, 25.79)	0.058
ESR (mm/h)	31.00 (15.00, 39.00)	23.00 (13.00, 34.01)	0.105
ALB (g/L)	35.70 (32.70, 39.80)	37.80 (34.73, 40.50)	0.049		0.613
WBC (× 109/L)	7.07 ± 2.21	6.24 ± 2.14	0.028	-0.248	0.008	0.780 (0.649, 0.939)
HBI	7 (6, 9)	6 (5, 8)	0.001	-0.029	0.018	0.812 (0.683, 0.965)
Previous abdominal surgery (yes), n (%)	4 (8.5)	14 (12.8)	0.437
Previous steroids or immunomodulators use (yes), n (%)	18 (38.3)	51 (46.8)	0.327

OR: Odds ratio; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; ALB: Albumin; WBC: White blood cell; HBI: Harvey-Bradshaw Index.